Spero Therapeutics, Inc. (NASDAQ:SPRO) Short Interest Update

Spero Therapeutics, Inc. (NASDAQ:SPRO) saw a significant drop in short interest during the month of February. As of February 27th, there was short interest totaling 574,027 shares, a drop of 19.8% from the February 12th total of 715,694 shares. Based on an average daily volume of 270,567 shares, the short-interest ratio is presently 2.1 days. Approximately 1.1% of the shares of the company are short sold. Approximately 1.1% of the shares of the company are short sold. Based on an average daily volume of 270,567 shares, the short-interest ratio is presently 2.1 days.

Insider Activity at Spero Therapeutics

In other news, insider Esther Rajavelu sold 87,917 shares of the business’s stock in a transaction on Friday, February 6th. The shares were sold at an average price of $2.36, for a total value of $207,484.12. Following the completion of the sale, the insider directly owned 1,012,091 shares in the company, valued at approximately $2,388,534.76. The trade was a 7.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Spero Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Invesco Ltd. acquired a new position in shares of Spero Therapeutics in the second quarter valued at $43,000. Millennium Management LLC acquired a new stake in Spero Therapeutics during the fourth quarter worth $56,000. Dimensional Fund Advisors LP bought a new stake in Spero Therapeutics in the 3rd quarter valued at $55,000. Quadrature Capital Ltd acquired a new position in shares of Spero Therapeutics in the 2nd quarter valued at $90,000. Finally, XTX Topco Ltd acquired a new position in shares of Spero Therapeutics in the 2nd quarter valued at $100,000. 25.60% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Spero Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen upgraded shares of Spero Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, January 11th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Spero Therapeutics has a consensus rating of “Reduce”.

Spero Therapeutics Stock Up 0.4%

SPRO stock opened at $2.59 on Tuesday. Spero Therapeutics has a twelve month low of $0.51 and a twelve month high of $3.22. The company has a market cap of $145.92 million, a PE ratio of -3.28 and a beta of 1.45. The business’s 50-day simple moving average is $2.37 and its 200 day simple moving average is $2.29.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.